Blextin is indicated for the symptomatic treatment of 
·  Allergic rhino-conjunctivitis (seasonal and perennial) and
· Urticaria. (Itchy skin & rashes)
Bilastine is also used to relieve the symptoms of hay fever (sneezing, itchy, runny, blocked-nose and red and watery eyes) and other forms of allergic rhinitis.

Adults and adolescents (12 years of age and over): 
Blextin 20 mg tablet (1tablet) once daily for the relief of symptoms of allergic rhino-conjunctivitis, urticaria and allergic rhinitis. The maximum recommended daily dose is 20 mg, which should be taken one hour before or two hours after intake of food or fruit juice.

Concomitant use of Bilastine with ketoconazole, erythromycin, cyclosporine or diltiazem increases the concentration of Bilastine. But these changes do not appear to affect the safety profile of any of the drugs. Intake of alcohol and 20 mg Bilastine shows same psychomotor performance similar to that of alchol and placebo. Concomitant intake of Bilastine 20 mg and lorazepam 3 mg for 8 days did not potentiate the depressant CNS effects of lorazepam.

Hypersensitivity to the active Substance of Bilastine or to any of the excipients.

Generally Bilastine is well tolerated. Side effects which may occur are headache, somnolence, dizziness, fatigue, anxiety, vertigo, abdominal pain etc.

Pregnancy: There are no adequate and well-controlled studies in pregnant women. Until such data become available, Bilastine should be used during pregnancy only if the potential benefit justifies the potential risk of the fetus.
Lactation: lt is not known whether Bilastine is excreted in human breast milk. So caution should be exercised if it is administered to a nursing mother.

Treatment with Bilastine 20 mg does not affect the driving performance. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.
ln clinical trials elderly patients (   65 years) showed no difference in efficacy or safety with respect to younger patients.
The maximum plasma conentration of Bilastine after administration of 20 mg in patients with severe renal impairment is below the safety threshold of most common adverse effects and cardiac or CNS safety. No dosage adjustment is necessary in patients with renal impairment. 
Bilastine is not metabolized in human. Since renal elimination is the major excretion, biliary excretion is expected to be only marginally involved in the elimination of Bilastine. Changes in liver function are not expected to have a clinically relevant influence.

· Keep below 300 C, protected from light & moisture.
· Keep out of the reach of the children.